The CDs’ influence on RA biological activity was also determined in terms of (i) antioxidant activity (studied in 2,2-diphenyl-1-picrylhydrazyl (DPPH), 2,2′-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) (ABTS), cupric reducing antioxidant capacity (CUPRAC), and ferric reducing antioxidant power assay (FRAP) methods); (ii) the inhibition of enzymes influencing the development of neurodegenerative diseases—acetylcholinesterase (AChE), butyrylcholinesterase (BChE), and tyrosinase. The gene discussed is ACHE; the disease is neurodegenerative disease.